注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
SCYNEXIS Inc是一家生物技术公司。该公司正在开发其主要候选产品ibrexafungerp,作为一种广谱静脉注射(IV)/口服制剂,用于社区和医院环境中的多种真菌适应症。它已获得美国食品和药物管理局(FDA)的批准,用于治疗外阴阴道念珠菌病(VVC,也称为阴道酵母感染)的BREXAFEMME(ibrexafungerp片剂)的新药申请(NDA)。BREXAFEMME是一种三萜类抗真菌药物,用于治疗患有外阴阴道念珠菌病(VVC)的成年和绝经后儿童女性。它还在继续进行ibrexafungerp的后期临床开发,以适应多种适应症,包括治疗住院患者中危及生命的侵袭性真菌感染。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Guy MacDonald | 62 | 2014 | Independent Chairman of the Board |
Steven C. Gilman | 70 | 2015 | Independent Director |
Philippe Tinmouth | 59 | 2019 | Independent Director |
Oliver Cornely | - | - | Member of Scientific Advisory Board |
Ann F. Hanham | 70 | 2008 | Independent Director |
Mahmoud Ghannoum | - | - | Member of Scientific Advisory Board |
David C. Hastings | 62 | 2015 | Independent Director |
Jack D. Sobel | - | - | Member of Scientific Advisory Board |
David W. Denning | - | - | Member of Scientific Advisory Board |
Luis Ostrosky-Zeichner | - | - | Member of Scientific Advisory Board |
Armando Anido | 65 | 2019 | Independent Director |
Barbara D. Alexander | - | - | Member of Scientific Advisory Board |
Paul Nyirjesy | - | - | Member of Scientific Advisory Board |
Peter G. Pappas | - | - | Member of Scientific Advisory Board |
David Gonzalez Angulo | 58 | 2015 | CEO, President & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核